Hibor (bemiparin) / ROVI Pharmaceuticals Laboratories, Elder Pharma - LARVOL DELTA

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Lung Cancer Receiving Chemotherapy (ASH 2023) - "The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban and apixaban were used in the studies. In our subgroup meta-analysis of POTP with DOACs, there was no statistically significant difference in reduction of VTE in LC patients with Khorana Score ≥2. Hence, the selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from POTP."

Retrospective data • Cardiovascular • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Liver Safety Comparison of Bemiparin and Enoxaparin in Pregnancy: Insights From a Real-World Study (ISPOR-EU 2025) - "This study suggested that enoxaparin was associated with a significantly higher incidence of liver injury events compared to bemiparin. Therefore, continuous monitoring of liver function is warranted when pregnant patients are treated especially with enoxaparin, and educating patients about the signs of liver injury such as abdominal pain or nausea is also crucial."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hepatology • Immunology • Liver Failure • Renal Disease • Venous Thromboembolism

Effect of Intra-arterial Bemiparin Sodium on Intestinal Ischemia-Reperfusion Injury: Animal Model. (PubMed, J Surg Res) - "Based on our findings in this rat model, intra-arterial bemiparin sodium may exert a protective effect against ischemia-reperfusion injury. Further studies are required to confirm its translational potential."

Journal • Preclinical • Cardiovascular • Gastrointestinal Disorder • Inflammation • Reperfusion Injury • CRP

Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy. (PubMed, Pediatr Res) - "Prophylactic LMWH started at the diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration. Its design is a randomized, triple-blind clinical trial, which provides high-quality evidence. LMWH is often prescribed during pregnancy for various indications, and in the absence of effective alternatives, it is increasingly used empirically in such cases. Our findings do not support its use for reducing perinatal morbidity or NICU admission duration."

Clinical • Journal

Whether an optimal strategy exists for VTE prevention in critically ill patients: Insights from guidelines and randomized controlled trials. (PubMed, Eur J Intern Med) - "Although the 17 CPGs propose various strategies for VTE prevention, substantial differences exist in their quality and clinical applicability. Existing clinical evidence fails to demonstrate superior prophylactic efficacy among VTE prevention strategies in critically ill patients."

Journal • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Anti-PF4/ Heparin Antibodies Early Seroconversion in Hip Fracture Patients Receiving Low Molecular Weight Heparin Prophylaxis: a Pilot Study of 100 Consecutive Patients. (PubMed, Arch Bone Jt Surg) - "Twenty-seven patients received bemiparin, 42 enoxaparin and 25 tinzaparin. These findings highlight the overall safety of LMWHs in elderly hip fracture patients. Moreover, the presence of anti-PF4/H appears unrelated to PLT fluctuations, subsequent VTE events and early postoperative mortality."

Journal • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Thrombocytopenia

Thromboprophylaxis in oncology patients with active cancer: results from GMaT and ACT4CAT clinical studies (MASCC-ISOO 2025) - "Anticoagulation agents were (%): 91.2 tinzaparin, 4.6 fondaparinux, 2.3 bemiparin, 1.2 enoxaparin, 0.8 rivaroxaban or apixaban, for 5.1±3.3 months duration. Selection of anticoagulation dose was based on demographics, cancer characteristics, treatment type and patient medical history. InterD was found to be more efficacious and without safety concerns."

Clinical • Metabolic Disorders • Oncology • Thrombosis

Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. (PubMed, Br J Clin Pharmacol) - "Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible."

Journal

Bemiparin in neonatal thrombosis: therapeutic dosing and safety. (PubMed, J Perinatol) - "Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Factor Xa Inhibitors and Low Molecular Weight Heparins in Perioperative Surgical Thromboprophylaxis: A Network Meta-Analysis. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Rivaroxaban, fondaparinux, edoxaban, and bemiparin are superior perioperative thromboprophylaxis agents than enoxaparin in major surgeries. Fondaparinux and bemiparin have shown the highest risk of major bleeding compared to other factor Xa inhibitors and LMWHs."

Clinical • Journal • Retrospective data • Cardiovascular • Hematological Disorders • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review. (PubMed, Aust N Z J Psychiatry) - "64.81% patients were on warfarin, 22.22% on a direct-acting oral anticoagulant, 5.55% on heparin and the rest on enoxaparin, dalteparin, acenocoumarol or bemiparin. This review showed tolerability of anticoagulants continued throughout electroconvulsive therapy, with most patients reporting no adverse effects. Given limitations including few studies and medical comorbidities influencing patient risk profile, further studies are required to guide practice recommendations and review long-term outcomes."

Journal • Review • Cardiovascular • Cerebral Hemorrhage • Psychiatry • Pulmonary Embolism • Respiratory Diseases

Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study) (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: AHEPA University Hospital | N=240 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Atrial Fibrillation • Cardiovascular • Oncology

PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LUNG CANCER UNDERGOING SYSTEMIC THERAPY: UPDATED ANALYSIS OF RANDOMIZED STUDIES (EHA 2024) - "5,526 patients with LC from five RCTs and subgroups of another six RCTs were eligible. Bemiparin, certoparin,dalteparin, nadroparin, semuloparin, tinzaparin, enoxaparin, rivaroxaban and apixaban were used. The durationof the anticoagulation ranged from 3 to 6 months."

Clinical • Cardiovascular • Hematological Disorders • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

BEMIPARIN IN ONCOLOGICAL PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2024) - "Our findings indicate that thromboprophylaxis with bemiparin had no statistically significant impact onlowering the risk of VTE in oncological patients. In addition, the results demonstrated no increased risk ofbleeding among these patients. Further RCTs are needed to assess more conclusively the extent of theseresults."

Retrospective data • Review • Cardiovascular • Oncology • Venous Thromboembolism

Anti-Xa level monitoring of low-molecular-weight heparin in patients with thrombosis and cancer (ISTH 2024) - "No statistically significant differences were observed between bemiparin and enoxaparin and tinzaparin for thrombosis and bleeding events. 447 results of anti-Xa activity from 50 patients were analyzed. 108 anti-Xa activity results (24.1%) were in the supratherapeutic range and 34 (7.6%) were infratherapeutic. A result out the therapeutic range in 21 anti-Xa determinations (34.2%) led to modification of the LMWH regimen."

Clinical • Cardiovascular • Hematological Disorders • Oncology • Pulmonary Embolism • Thrombosis • Venous Thromboembolism

Anticoagulants In The Treatment of Primary Antiphospholipid Syndrome In Pregnant Women: A Systematic Review (ISTH 2024) - "Through the inclusion criteria, 3 journals were obtained according to the Randomized Control Trial (RCT), Cohort, and Clinical Trial research description. Based on the Newcastle Ottawa Scale (NOS) and the Jadad Scale, 2 studies were rated good and 1 studies were fair. Based on this research, it was found that in patients with primary antiphospholipid syndrome, the use of anticoagulants with and without low dose aspirin (LDA) resulted in a high live birth rate ranging from 82-86.25%."

Clinical • Review • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Thrombosis

Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly. (PubMed, J Eval Clin Pract) - "Bemiparin showed a similar efficacy and safety profile in the treatment of venous thromboembolic disease in elderly and adult patients."

Journal • Cardiovascular • Geriatric Disorders • Venous Thromboembolism

ACT for patients with active cancer and high thromboembolic risk: results from the ACT4CAT study (MASCC-AFSOS-ISOO 2024) - "Anticoagulants were: tinzaparin 88.5%, fondaparinux 6.1%, bemiparin 2.5%, enoxaparin 1.7%, apixaban 0.6% and rivaroxaban 0.7%. Conclusions Thromboprophylaxis in patients with active ca is safe & effective. Metastasis, HRTCAs & drug-drug interactions seem that influence a decision for thromboprophylaxis in favor of LMWHs, often on intermediate dose."

Clinical • Cardiovascular • CNS Disorders • Hematological Disorders • Oncology

TRACIP: Treatment of Intrauterine Growth Restriction With Low Molecular Heparin. (clinicaltrials.gov) - P3 | N=48 | Completed | Sponsor: Fundació Sant Joan de Déu | Unknown status ➔ Completed

Trial completion

Treatment with reversible coagulation inhibitors does not provides full coagulation inhibition. (GTH 2024) - "Testing oral anticoagulation with vitamin K antagonists (Warfarin) or with heparinoids (unfractionated heparin, LMW heparin such as Fragmin, Enoxaparin, Bemiparin, and Fondaparinux) showed for heparinoids a similar delay and stop of growth, but surprisingly for vitamin K antagonists a reduced but not a stop of growth...Testing reversible inhibitors of factor Xa (Rivaroxaban, Apixaban, Edoxaban) and of factor IIa (Dabigatran, Argatroban) showed a maximal reduction of about 50% in growth for quite a prolonged time (> 1 hr), but no stop...The profile of the inhibitors may be used to match the clinical need and the pathological process. The suggestion can be made that new Xa-DOACs may be selected to be more potent, tight inhibitors of the factor Xa formed by the intrinsic tenase (factor IX, factor VIII) which is involved in clot growth."

unilateral purpura associated to deep vein thrombosis (EADV 2023) - "The decision was to continue the antibacillary treatment under strict hepatic surveillance, to put the patient on antibiotics based on ceftriaxone 2 grams per day and anticoagulant (bemiparin 5000 ui per day), thereafter the purpura began to regress; and on the dermatological level to carry out a thrombophilia and paraneoplastic assessment and a skin biopsy; the patient refused the treatment and left against medical advice. Purpura is a rare sign of deep vein thrombosis. Our observation is original as it is the third case described."

Anemia • Cardiovascular • Dermatology • Hematological Disorders • Infectious Disease • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • Tuberculosis • Venous Thromboembolism • Venous Ulcer • RIPK4

Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies (IASLC-WCLC 2023) - "Main antithrombotic agents were: tinzaparin 90.6%, fondaparinux 5.9%, bemiparin 2.8% and enoxaparin 0.7%. Primary prophylaxis in ambulatory LC patients, mainly with Low Molecular Weight Heparins (LMWHs), and more frequently in intermediate dose in high thrombotic burden metastatic LC patients, was both effective and safe. LMWHs did not increase bleeding risk and there was no reported interference with the anticancer treatment. Further clinical research is needed."

Clinical • Cardiovascular • Hematological Disorders • Lung Cancer • Oncology • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Venous Thromboembolism

BRIF: Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure (clinicaltrials.gov) - P4 | N=165 | Completed | Sponsor: American University of Beirut Medical Center | Recruiting ➔ Completed

Trial completion • MTHFR

New low molecular weight heparin antidote based on an antithrombin mutant (ISTH 2023) - "In an ex vivo assay, plasma from patients (n=4) treated with LMWH (60 mg/12 hours of enoxaparin or 7500 IU/day of bemiparin) was used to measure anti-FXa activity in a coagulometer by adding different concentrations of the antidote. This antidote showed neither anti-FXa nor anti-FIIa activity, was expressed 2.7-fold higher than wild-type beta antithrombin, and also had an affinity for LMWH 2.6-fold higher than wild-type beta antithrombin. Plasma from mice injected with antidote or the heparin/antidote combination showed significantly higher FXa activity than mice injected with heparin. Additionally, the antidote completely reversed the anti-FXa activity at a dose of 2.14 µM in plasma of patients anticoagulated with LMWH.Conclusion(s): Our results demonstrate that this recombinant molecule, by pleiotropic actions, could be effective in blocking the anticoagulant effect of LMWH."

Real world data for venous thromboembolisms (VTEs) in patients with active cancer: Thromboprophylaxis pooled analysis from GMaT and ACT4CAT studies. (ASCO 2023) - P=N/A | "Thromboprophylaxis duration was 5.1±3.3 months with: tinzaparin 91.2%, fondaparinux 4.6%, bemiparin 2.3%, enoxaparin 1.2%, rivaroxaban 0.4% and apixaban 0.3%. VTEs prophylaxis in ambulatory patients with active cancer was found safe and effective. Apart from Khorana score, metastasis, HRTAs and DDIs seem to affect clinical decision for thromboprophylaxis mainly with LMWHs and often using intermediate doses irrelevant of clinical setting. Cancer Associated Thrombosis (CAT) is not negligible risk for patients and oncologists appeared to be aware about this."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Oncology • Urology • Venous Thromboembolism